V1P

V1P is an experimental **PEGylated netrin-1-derived small peptide** being investigated as a therapy for **pulmonary hypertension**. It is a modified version of the native netrin-1-derived V1 peptide, designed to improve **stability, permeability, and resistance to oxidative degradation**. Based on the provided preclinical study, V1P is intended to bind and activate the **Deleted in Colorectal Carcinoma receptor**, thereby promoting **ERK1/2-eNOS signaling**, restoring **nitric oxide bioavailability**, reducing **oxidative stress** and **mitochondrial superoxide**, and reversing **eNOS uncoupling**. In hypoxia-exposed mice, V1P reduced mean pulmonary arterial pressure, right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling. The available evidence is preclinical and appears to come from academic research led at UCLA rather than from a named commercial development program.

Other names

PEGylated V1 peptidePEG-conjugated netrin-1-derived V1 peptide